Skip to content

Omega 3, Leucine, Probiotic Lactobacillus Paracasei PS23 on Muscle Mass in Sarcopenic Subjects

Randomized, Placebo-controlled Clinical Study to Evaluate the Effect of 2 Months of Nutritional Support Based on Omega 3, Leucine, Probiotic Lactobacillus Paracasei PS23 (OLEP Study) on Muscle Mass in Sarcopenic Subjects

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04702087
Enrollment
54
Registered
2021-01-08
Start date
2021-01-22
Completion date
2022-12-31
Last updated
2021-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly, Omega 3, Sarcopenia

Brief summary

The purpose of the study is to evaluate the effect of supplementation with a nutritional blend based on Omega 3 fatty acids, the probiotic leucine Lactobacillus paracasei PS23 (OLEP), on muscle mass recovery in sarcopenic patients.

Interventions

DIETARY_SUPPLEMENTOLEP

omega 3 (500 mg), leucine (2,5 g), probiotic Lactobacillus paracasei PS23

COMBINATION_PRODUCTPlacebo

Isocaloric formula

Sponsors

Abiogen Pharma
CollaboratorINDUSTRY
Azienda di Servizi alla Persona di Pavia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Sarcopenic patients (diagnosis made according to the criteria Revised European Consensus on Definition and Diagnosis) * Body Mass Index between 20 and 30 Kg/m2

Exclusion criteria

* severe renal failure (glomerular filtration rate \< 30 mL/min) * moderate to severe liver failure (Child-Pugh class B or C) * endocrine diseases associated with calcium metabolism disorders (except osteoporosis) * known psychiatric disorders * cancer (over the past 5 years) * hypersensitivity to any component of the investigational nutritional supplement and * taking to protein/amino acid supplements (up to 3 months before starting the study) * patients unable to take oral therapy * receiving or with indication for artificial nutrition * who had been included in another clinical nutrition trial

Design outcomes

Primary

MeasureTime frameDescription
Changes on muscle massBaseline / 30 days / 60 daysEvaluation of fat free mass (g)

Secondary

MeasureTime frameDescription
Changes on physical performancyBaseline / 60 daysEvaluation of Tinetti scale (point scale) that measures characteristics associated with falls, assessing balance (14 items; 24 points), and gait (10 items; 16 points) for a total score up to 40 (the higher the score, the better the performance)
Changes on functional statusBaseline / 60 daysEvaluation of Barthel Index (point scale) (covering all the aspects of self-care independence in daily living activities, including transfer, walking, stairs, toilet use, dressing, feeding, bladder, bowel, grooming, and bathing; score range, 0 (completely dependent) -100 (complete self-sufficiency))
Changes on muscle strengthBaseline / 30 days / 60 daysEvaluation of muscle strength (kg)
Changes on Quality of lifeBaseline / 60 daysEvaluation of Short-Form 12-Item Health Survey (poin survey): a generic health-status measure (physical component summary score and the mental component summary score) by addressing eight health domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. Score from 0 (bad quality) to 100 (high quality).
Changes on body compositionBaseline / 30 days / 60 daysEvaluation of fat mass (g) and visceral adipose tissue (g)
Changes on blood pressureBaseline / 60 daysEvaluation of systolic and diastolic pressure (mm/Hg)
Changes on plasma free essential amino acidsBaseline / 60 daysEvaluation of free essential amino acids in plasma (Leucine, Isoleucine, Valine) (micromol/L)
Changes on safety parametersBaseline / 60 daysEvaluation of creatinine (mg/dl)
Changes on moodBaseline / 60 daysEvaluation of Geriatric Depression Scale (point scale). a 30-question test with yes/no answers. 10 - 15 Points: Probable presence of depression; 6 - 9 Points: Depression possible; 0 - 5 Points: Unlikely Depression.

Countries

Italy

Contacts

Primary ContactMariangela Rondanelli
mariangela.rondanelli@unipv.it+390382381749

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026